ClinicalTrials.gg
Status unknownNCT00009061Updated Jun 24, 2005

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

A Phase 3 interventional study of Ritonavir and Abacavir sulfate in HIV Infections, sponsored by Glaxo Wellcome. Status unknown at 37 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2002), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
624
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.

Enrollment
6th of 119
624 · median 46
Started
2000
with 4 others
Phase 3
24 of 124
1 open now
Registered
26th of 124
by date

Among the 124 studies testing ritonavir in HIV Infections, this one is the 6th largest by enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2000, is one of 24 in phase 3, and was the 26th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:

About ritonavir

Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies testing ritonavir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.

Read the detailed description

Patients are randomized to 1 of 2 treatment arms. One arm is treated with GW433908/RTV plus ABC and 3TC. The other is treated with NFV plus ABC and 3TC. Each group is treated for 48 weeks. The following are compared in the 2 arms: 1) magnitude and durability of antiviral response; 2) safety, tolerance, and antiviral response after 24 and 48 weeks of therapy; 3) time to treatment failure; 4) immunologic response; 5) occurrence of events related to metabolic abnormalities; and 6) development of viral resistance in a subset of patients following treatment. Also studied are: 1) steady-state plasma drug trough concentrations; 2) demographic, virologic, immunologic, pharmacologic, and adherence factors that may be associated with treatment outcome; 3) patient adherence to the drug regimens; 4) study medication utilization; and 5) resource utilization.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • HIV Protease Inhibitors
  • Ritonavir
  • Lamivudine
  • Nelfinavir
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • abacavir
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 13 years old (consent of parent or guardian needed if under 18).
  • Agree to use a proven barrier method of (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children.
  • Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI). Mothers who have previously received 1 dose of the NNRTI nevirapine during pregnancy for prevention of mother-to-child transmission are permitted to enter the study.
  • Have a viral load (amount of HIV in the blood) of 1,000 copies/ml or more.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Abuse drugs or alcohol in a way that would interfere with study requirements. Patients who are stable on methadone will be considered for the study.
  • Have an active/acute CDC Category C event.
  • Are unable to absorb or take medicines by mouth.
  • Are pregnant or breast-feeding.
  • Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient.
  • Have had pancreatitis or hepatitis within the last 6 months.
  • Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study.
  • Have taken drugs that affect the immune system (such as , interleukins, interferons) or that have anti- activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken.
  • Have received an HIV vaccine within 3 months before the study drug will be taken.
  • Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study.
  • Have received experimental treatments.
  • Have allergies which might interfere with the study, in the opinion of the doctor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
624 participants
06

Study locations

37 sites
  • Orange County Ctr for Special Immunology
    Fountain Valley, California 92708, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 90027, United States
  • LAGLC
    Los Angeles, California 90028, United States
  • Kaiser Hospital
    Sacramento, California 95825, United States
  • Park Ctr for Health / Keith Vrhel
    San Diego, California 92103, United States
  • AIDS Research Alliance
    West Hollywood, California 90069, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • Infectious Disease Consultants
    Altamonte Springs, Florida 32701, United States
  • CRI of South Florida
    Coral Gables, Florida 33146, United States
  • Therafirst Med Ctr
    Fort Lauderdale, Florida 33308, United States
  • Gary Richmond MD
    Fort Lauderdale, Florida 33316, United States
  • Univ of Miami Dept of Medicine
    Miami, Florida 33136, United States
  • Specialty Med Care Ctrs of South Florida Inc
    Miami, Florida 33142, United States
  • Infectious Diseases Associates
    Sarasota, Florida 34239, United States
  • Jeffrey Levenson
    St. Petersburg, Florida 33710, United States
  • Infectious Disease Research Inst
    Tampa, Florida 33614, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Med College of Georgia
    Augusta, Georgia 30912, United States
  • SMO USA
    Conyers, Georgia 30013, United States
  • Indiana Univ Med School
    Indianapolis, Indiana 46202, United States
  • Brigham and Women's Hosp
    Boston, Massachusetts 02115, United States
  • Hawthorne Med Associates / PAACA
    New Bedford, Massachusetts 02745, United States
  • Abbott-Northwestern Hosp / Clinic 42
    Minneapolis, Minnesota 55404, United States
  • Southampton Healthcare Inc
    St. Louis, Missouri 63139, United States
  • VAMC New Jersey Healthcare System
    East Orange, New Jersey 07018, United States
  • North Jersey Community Research Initiative
    Newark, New Jersey 071032842, United States
  • Bronx Veterans Affairs Med Ctr
    Bronx, New York 10468, United States
  • SUNY / Erie County Med Ctr at Buffalo
    Buffalo, New York 14215, United States
  • North Shore Univ Hosp
    Manhasset, New York 11030, United States
  • St Lukes - Roosevelt Hosp Ctr
    New York, New York 10019, United States
  • Univ of Cincinnati / Holmes Hosp
    Cincinnati, Ohio 452670405, United States
  • Milton S Hershey Med Ctr
    Hershey, Pennsylvania 170330850, United States
  • Hahnemann Univ Hosp
    Philadelphia, Pennsylvania 19102, United States
  • Burnside Clinic
    Columbia, South Carolina 29206, United States
  • Methodist Healthcare
    Memphis, Tennessee 38104, United States
  • Nicholas Bellos
    Dallas, Texas 75246, United States
  • Joseph C Gathe
    Houston, Texas 77004, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00009061
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Start date
Nov 2000
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ritonavir · Abacavir · Nelfinavir · Lamivudine · Fosamprenavir

Start the discussion